Literature DB >> 20652393

Obesity is associated with improved survival in patients with organ-confined clear-cell kidney cancer.

Sandra Waalkes1, Axel S Merseburger, Mario W Kramer, Thomas R W Herrmann, Gerd Wegener, Julia Rustemeier, Rainer Hofmann, Mark Schrader, Markus A Kuczyk, Andres J Schrader.   

Abstract

OBJECTIVES: Obesity increases the risk of developing renal cell carcinoma (RCC); however, it remains unclear whether obesity is associated with RCC aggressiveness and survival. We assessed whether different body mass index (BMI) levels at the time of surgery had an effect on long-term prognosis of RCC patients.
METHODS: We evaluated 1,338 clear-cell RCC patients with complete information about their BMI, who had undergone surgery for renal cell cancer at the University Hospitals in Hannover and Marburg between 1991 and 2005. The mean follow-up was 5.1 years.
RESULTS: Underweight, normal weight, pre-obesity, and obesity were diagnosed in 14 (1.0%), 444 (33.2%), 593 (44.3%), and 287 (21.4%) RCC patients, respectively. A lower BMI was significantly associated with higher age, tumor grade, and the rate of metastasis at diagnosis. Overweight patients had a significantly lower risk of cancer-related death; their median 5-year tumor-specific survival rate was 70.9% (pre-obese), 74.0% (obese grad I), and 85.6% (obese grad ≥II) as opposed to 63.8% for patients with a BMI below 25 (p < 0.001). Interestingly, subgroup analysis revealed that the positive association between overweight and survival was found in organ-confined RCC only.
CONCLUSION: We identified overweight as an independent prognostic marker of improved cancer specific survival in patients with organ-confined but not advanced RCC. Basic research is required to resolve the dilemma of why, if a higher BMI predisposes to RCC, it concurrently prolongs survival after patients have undergone (partial) nephrectomy.

Entities:  

Mesh:

Year:  2010        PMID: 20652393     DOI: 10.1007/s10552-010-9618-2

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  23 in total

1.  Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma.

Authors:  Kenneth R Carson; Nancy L Bartlett; Jay R McDonald; Suhong Luo; Angelique Zeringue; Jingxia Liu; Qiang Fu; Su-Hsin Chang; Graham A Colditz
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

2.  The role of body mass index in survival outcome for lymphoma patients: US intergroup experience.

Authors:  F Hong; T M Habermann; L I Gordon; H Hochster; R D Gascoyne; V A Morrison; R I Fisher; N L Bartlett; P J Stiff; B D Cheson; M Crump; S J Horning; B S Kahl
Journal:  Ann Oncol       Date:  2014-03       Impact factor: 32.976

3.  [Overweight is an advantageous prognostic marker in patients with clear cell kidney cancer].

Authors:  S Waalkes; H Eggers; J Rustemeier; G Wegener; F Jentzmik; M Schrader; R Hofmann; M A Kuczyk; A J Schrader
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

4.  Obesity adversely impacts disease specific outcomes in patients with upper tract urothelial carcinoma.

Authors:  Behfar Ehdaie; Thomas F Chromecki; Richard K Lee; Yair Lotan; Vitaly Margulis; Pierre I Karakiewicz; Giacomo Novara; Jay D Raman; Casey Ng; William T Lowrance; Douglas S Scherr; Shahrokh F Shariat
Journal:  J Urol       Date:  2011-05-14       Impact factor: 7.450

5.  The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436).

Authors:  Vicki A Morrison; Linda McCall; Hyman B Muss; Aminah Jatoi; Harvey J Cohen; Constance T Cirrincione; Jennifer A Ligibel; Jacqueline M Lafky; Arti Hurria
Journal:  J Geriatr Oncol       Date:  2017-12-08       Impact factor: 3.599

6.  Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials.

Authors:  Suzanne E Dahlberg; Joan H Schiller; Philip B Bonomi; Alan B Sandler; Julie R Brahmer; Suresh S Ramalingam; David H Johnson
Journal:  J Thorac Oncol       Date:  2013-09       Impact factor: 15.609

7.  Evaluating adherence to recommended diets among cancer patients.

Authors:  Hye In Kim; Kyunga Kim; Jung Eun Lee
Journal:  Support Care Cancer       Date:  2011-11-12       Impact factor: 3.603

8.  Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy?

Authors:  Sandra Steffens; Viktor Grünwald; Kristina I Ringe; Christoph Seidel; Hendrik Eggers; Mark Schrader; Frank Wacker; Markus A Kuczyk; Andres J Schrader
Journal:  Oncologist       Date:  2011-10-21

9.  A Critical Analysis of Perioperative Outcomes in Morbidly Obese Patients Following Renal Mass Surgery.

Authors:  Matthew D Grimes; Michael L Blute; Tyler A Wittmann; Michael A Mann; Kristin Zorn; Tracy M Downs; Fangfang Shi; David F Jarrard; Sara L Best; Kyle A Richards; Stephen Y Nakada; E Jason Abel
Journal:  Urology       Date:  2016-06-23       Impact factor: 2.649

Review 10.  Effects of obesity on immune responses to renal tumors.

Authors:  Vincent Chehval; Lyse A Norian
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.